Thallion Pharma Q3 revenue rises
Thallion Pharma has posted a net loss of $351,394 for the third quarter 2010, or $0.01 loss per diluted share, compared to net loss of $3.03m, or $0.09
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
The seven Europeon countries in the agreement include Bosnia, Croatia, Finland, Macedonia, Montenegro, Serbia and Slovenia. Health Robotics said that its software and related technologies will finally enable